{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:22:08Z","timestamp":1790400128814,"version":"4.1.0"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T00:00:00Z","timestamp":1315526400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0024370","type":"journal-article","created":{"date-parts":[[2011,9,10]],"date-time":"2011-09-10T01:43:24Z","timestamp":1315619004000},"page":"e24370","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":57,"title":["Association of Inherited Variation in Toll-Like Receptor Genes with Malignant Melanoma Susceptibility and Survival"],"prefix":"10.1371","volume":"6","author":[{"given":"Andreas","family":"Gast","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justo Lorenzo","family":"Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Claus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Weires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Plass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Sucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,9,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CMR.0b013e32832eabd5","article-title":"Spontaneous regression of metastases from melanoma: review of the literature.","volume":"19","author":"LV Kalialis","year":"2009","journal-title":"Melanoma Res"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJM198806163182401","article-title":"Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells.","volume":"318","author":"MB Atkins","year":"1988","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa053007","article-title":"Prognostic significance of autoimmunity during treatment of melanoma with interferon.","volume":"354","author":"H Gogas","year":"2006","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1200\/JCO.2001.19.15.3477","article-title":"Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.","volume":"19","author":"GQ Phan","year":"2001","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/90609","article-title":"Toll-like receptors: critical proteins linking innate and acquired immunity.","volume":"2","author":"S Akira","year":"2001","journal-title":"Nat Immunol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1600-065X.2007.00572.x","article-title":"Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity.","volume":"220","author":"AM Krieg","year":"2007","journal-title":"Immunol Rev"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.onc.1210906","article-title":"Toll-like receptors and immune regulation: implications for cancer therapy.","volume":"27","author":"RF Wang","year":"2008","journal-title":"Oncogene"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.bbrc.2009.08.062","article-title":"Toll-like receptors and innate immunity.","volume":"388","author":"H Kumar","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/0-387-24180-9_2","article-title":"Toll-like receptors: linking innate and adaptive immunity.","volume":"560","author":"C Pasare","year":"2005","journal-title":"Adv Exp Med Biol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1042\/CS20070214","article-title":"Toll-like receptor polymorphisms and susceptibility to human disease.","volume":"114","author":"EA Misch","year":"2008","journal-title":"Clin Sci (Lond)"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"S403","DOI":"10.1086\/431985","article-title":"Polymorphisms of the Toll-like receptors and human disease.","volume":"41","author":"DA Schwartz","year":"2005","journal-title":"Clin Infect Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/sj.onc.1210912","article-title":"Polymorphisms in Toll-like receptor genes and risk of cancer.","volume":"27","author":"EM El-Omar","year":"2008","journal-title":"Oncogene"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nri1957","article-title":"Toll-like receptors in systemic autoimmune disease.","volume":"6","author":"A Marshak-Rothstein","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S1470-2045(03)01280-4","article-title":"Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.","volume":"4","author":"TK Eigentler","year":"2003","journal-title":"Lancet Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1586\/era.09.25","article-title":"Current systemic therapy for metastatic melanoma.","volume":"9","author":"SS Agarwala","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/nature07830","article-title":"The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex.","volume":"458","author":"BS Park","year":"2009","journal-title":"Nature"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"322","DOI":"10.4049\/jimmunol.177.1.322","article-title":"Analysis of TLR4 polymorphic variants: new insights into TLR4\/MD-2\/CD14 stoichiometry, structure, and signaling.","volume":"177","author":"P Rallabhandi","year":"2006","journal-title":"J Immunol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-065X.2007.00573.x","article-title":"The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.","volume":"220","author":"L Apetoh","year":"2007","journal-title":"Immunol Rev"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin.","volume":"29","author":"A Tesniere","year":"2010","journal-title":"Oncogene"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1158\/1055-9965.EPI-08-0981","article-title":"Toll-like receptor signaling pathway variants and prostate cancer mortality.","volume":"18","author":"JR Stark","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.1203\/PDR.0b013e3181e6a068","article-title":"Role of Polymorphic Variants as Genetic Modulators of Infection in Neonatal Sepsis.","author":"A Abu-Maziad","year":"2010","journal-title":"Pediatr Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1086\/524688","article-title":"Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy.","volume":"197","author":"PY Bochud","year":"2008","journal-title":"J Infect Dis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/sj.gene.6364405","article-title":"A polymorphism in human TLR2 is associated with increased susceptibility to tuberculous meningitis.","volume":"8","author":"NT Thuong","year":"2007","journal-title":"Genes Immun"},{"key":"ref24","first-page":"2905","article-title":"Association of toll-like receptor 2 gene polymorphisms with normal tension glaucoma.","volume":"15","author":"J Nakamura","year":"2009","journal-title":"Mol Vis"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jaci.2008.04.039","article-title":"Toll-like receptor heterodimer variants protect from childhood asthma.","volume":"122","author":"MS Kormann","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jaci.2003.12.374","article-title":"Toll-like receptor 2 as a major gene for asthma in children of European farmers.","volume":"113","author":"W Eder","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1196\/annals.1375.040","article-title":"No association of TLR2 and TLR4 polymorphisms with type I diabetes mellitus in the Basque population.","volume":"1079","author":"I Santin","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00439-004-1249-9","article-title":"TLR2 Arg677Trp polymorphism in leprosy: revisited.","volume":"116","author":"D Malhotra","year":"2005","journal-title":"Hum Genet"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"11771","DOI":"10.1158\/0008-5472.CAN-05-2078","article-title":"Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer.","volume":"65","author":"YC Chen","year":"2005","journal-title":"Cancer Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/1055-9965.EPI-06-0429","article-title":"Toll-like receptor 4 genetic variation and advanced prostate cancer risk.","volume":"16","author":"I Cheng","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/pros.20933","article-title":"Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II.","volume":"69","author":"MH Wang","year":"2009","journal-title":"Prostate"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0024370","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T23:00:36Z","timestamp":1540335636000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0024370"}},"subtitle":[],"editor":[{"given":"Stefan","family":"Bereswill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,9,9]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2011,9,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0024370","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,9]]}}}